Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study
Journal of Neuro-Oncology · 2025
DOI: 10.1007/s11060-025-05162-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Maya Jeje Schuang Lü und 9 weiteren Autor:innen. Beteiligte Einrichtung: Danish Comprehensive Cancer Center, Brain Tumor Center (DCCC-BTC), Blegdamsvej 9, Copenhagen, 2100, Denmark. Hauptthemen laut MEDLINE: Glioblastoma, Bevacizumab, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital.
Abstract (Originalsprache)
Purpose
Bevacizumab combination treatment rechallenge in glioblastoma (GBM) patients who initially responded at recurrence has shown renewed responses in up to 60% of cases, with associated survival benefits. This study sought to characterise such repeat responders and identify predictive biomarkers.
Methods
A total of 254 IDHwt GBM patients treated with bevacizumab plus chemotherapy (BevCT) were evaluated for eligibility. Five patients met the inclusion criteria for this case study by exhibiting repeated responses to BevCT and having tumour tissue available for molecular analysis. Histopathological re-assessments were performed to confirm GBM diagnoses. Angiotensinogen (AGT) promoter methylation status was analysed in all primary tumour samples, while bulk RNA sequencing and TSO500 assays were conducted on all available samples.
Results
In our cohort, 40% of patients who were rechallenged with BevCT following a treatment pause exhibited a response both during the initial course and upon rechallenge. Bulk RNA sequencing revealed downregulation of HILPDA and IGF2 as potentially predictive of repeated bevacizumab response. Additionally, AGT promoter methylation analysis identified high methylation levels as another potential predictive biomarker.
Conclusions
A subgroup of GBM patients responds to BevCT up to three times in the recurrent setting, and these repeated responders exhibit prolonged survival. No definitive prognostic variables or histopathological features were found in this study. Further investigation into the downregulation of HILPDA and IGF2, along with high AGT promoter methylation levels and other potential predictive biomarkers, is warranted to better understand the mechanisms underlying repeated BevCT response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Danish Comprehensive Cancer Center, Brain Tumor Center (DCCC-BTC), Blegdamsvej 9, Copenhagen, 2100, Denmark.
- The Finsen Laboratory, Rigshospitalet, Ole Maaløes Vej 5, Copenhagen, 2100, Denmark.
- Biotech Research and Innovation Center (BRIC), University of Copenhagen, Ole Maaløes Vej 5, Copenhagen, 2100, Denmark.
- Department of Oncology, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark.
- The Regional Department of Clinical Microbiology, University Hospital of Region Zealand, Køge, 4600, Denmark.
- Department of Pathology, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark.
Förderung
- National Hospital
Zitieren
APA
Lü, M. J. S., Michaelsen, S. R., Locallo, A., Eickhart-Dalbøge, C. S., Scheie, D., Melchior, L. C., Weischenfeldt, J., Lassen, U., Poulsen, H. S., & Urup, T. (2025). Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05162-2
Vancouver
Lü MJS, Michaelsen SR, Locallo A, Eickhart-Dalbøge CS, Scheie D, Melchior LC, et al. Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-05162-2
BibTeX
@article{L2025,
author = {Lü, Maya Jeje Schuang and Michaelsen, Signe Regner and Locallo, Alessio and Eickhart-Dalbøge, Christina Schjellerup and Scheie, David and Melchior, Linea Cecilie and Weischenfeldt, Joachim and Lassen, Ulrik and Poulsen, Hans Skovgaard and Urup, Thomas},
title = {Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study},
journal = {Journal of Neuro-Oncology},
year = {2025},
doi = {10.1007/s11060-025-05162-2}
}
EUVIMED